Infective endocarditis in pregnant women without intravenous drug use: a multicentre retrospective case series.

OBJECTIVES To describe the clinical features and outcomes of infective endocarditis (IE) in pregnant women who do not inject drugs. METHODS A multinational retrospective study was performed at 14 hospitals. All definite IE episodes between January 2000 and April 2021 were included. The main outcomes were maternal mortality and pregnancy-related complications. RESULTS Twenty-five episodes of IE were included. Median age at IE diagnosis was 33.2 years (IQR 28.3-36.6) and median gestational age was 30 weeks (IQR 16-32). Thirteen (52%) patients had no previously known heart disease. Sixteen (64%) were native IE, 7 (28%) prosthetic and 2 (8%) cardiac implantable electronic device IE. The most common aetiologies were streptococci (n = 10, 40%), staphylococci (n = 5, 20%), HACEK group (n = 3, 12%) and Enterococcus faecalis (n = 3, 12%). Twenty (80%) patients presented at least one IE complication; the most common were heart failure (n = 13, 52%) and symptomatic embolism other than stroke (n = 4, 16%). Twenty-one (84%) patients had surgery indication and surgery was performed when indicated in 19 (90%). There was one maternal death and 16 (64%) patients presented pregnancy-related complications (11 patients ≥1 complication): 3 pregnancy losses, 9 urgent Caesarean sections, 2 emergency Caesarean sections, 1 fetal death, and 11 preterm births. Two patients presented a relapse during a median follow-up of 3.1 years (IQR 0.6-7.4). CONCLUSIONS Strict medical surveillance of pregnant women with IE is required and must involve a multidisciplinary team including obstetricians and neonatologists. Furthermore, the potential risk of IE during pregnancy should never be underestimated in women with previously known underlying heart disease.

[1]  V. Fowler,et al.  Maternal and fetal outcomes associated with infective endocarditis in pregnancy. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Steve W Leung,et al.  Infective endocarditis in pregnancy from 2009 to 2019: the consequences of injection drug use , 2021, Infectious diseases.

[3]  B. Almirante,et al.  Secular trends in the epidemiology and clinical characteristics of Enterococcus faecalis infective endocarditis at a referral center (2007–2018) , 2021, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  K. Rood,et al.  Infective Endocarditis as a Complication of Intravenous Drug Use in Pregnancy: A Retrospective Case Series and Literature Review , 2020, American Journal of Perinatology Reports.

[5]  M. Veve,et al.  Maternal Bacteremia Caused by Staphylococcus Aureus With a Focus on Infective Endocarditis , 2020, Open forum infectious diseases.

[6]  J. Roos‐Hesselink,et al.  Pregnancy and cardiovascular disease , 2020, Nature Reviews Cardiology.

[7]  O. Alfieri,et al.  Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. , 2019, European heart journal.

[8]  Susanna Price,et al.  2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). , 2015, European heart journal.

[9]  S. Yuan Infective Endocarditis during pregnancy. , 2015, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[10]  M. Murad,et al.  Pregnancy and postpartum infective endocarditis: a systematic review. , 2014, Mayo Clinic proceedings.

[11]  B. Seifert,et al.  Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996. , 1998, American journal of obstetrics and gynecology.